secwatch.observer — SEC 8-K summary
======================================

Issuer:     Avalo Therapeutics, Inc. (AVTX)
CIK:        0001534120
Form:       8-K
Filed at:   2025-10-01T23:59:59+00:00
Accession:  0001534120-25-000009
Event type: leadership
Sentiment:  positive
Materiality: 0.45
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Avalo Therapeutics expands leadership with CBO and SVP HR appointments
----------------------------------------------------------------------

- Taylor Boyd named Chief Business Officer; base salary $465k, target bonus 40%, 275k stock option inducement grant.
- Ashley Ivanowicz appointed SVP, Human Resources; receives 100k stock option inducement grant.
- Both options vest over 4 years with 12-month cliff; granted under Nasdaq inducement rule.
- Company advancing AVTX-009 in Phase 2 LOTUS trial for hidradenitis suppurativa; data readout expected mid-2026.
- Boyd previously led BD at Longboard, culminating in $2.6B acquisition by Lundbeck.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1534120/000153412025000009/0001534120-25-000009-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1534120/000153412025000009/avtx-20250929.htm
  HTML page:      https://secwatch.observer/filing/0001534120-25-000009

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer